Table 1.
Socio-demographic and clinical characteristics of patients treated with chemotherapy (CT+) and a control group (CT−)
| N (%) | |||
|---|---|---|---|
| Group CT− a (n = 43) | Group CT+ b (n = 88) | p Value | |
| Socio-demographics | |||
| Age (mean (min/max) SD) | 61 (36/79) 11.4 | 62 (36/81) 10.0 | ns |
| Gender | ns | ||
| Male | 19 (44) | 39 (44) | |
| Female | 24 (56) | 49 (56) | |
| Indication | ns | ||
| Neo-adjuvant | 1 (2) | 4 (5) | |
| Adjuvant | 17 (40) | 36 (41) | |
| Curative | 2 (5) | 7 (8) | |
| Palliative | 23 (53) | 41 (47) | |
| Type of malignancy | ns | ||
| Breast | 7 (16) | 13 (15) | |
| Colon | 16 (37) | 29 (33) | |
| Sigmoïd | 3 (7) | 9 (10) | |
| Rectal | 9 (21) | 7 (8) | |
| Gastric | 0 | 6 (7) | |
| Non Hodgkin lymphoma | 1 (2) | 8(9) | |
| Prostate | 0 | 7 (8) | |
| Ovarian | 2 (5) | 5 (6) | |
| Pseudo myxoma peritonei | 1 (2) | 0 | |
| Lung | 0 (0) | 1 (1) | |
| Endometrial | 0 (0) | 2 (2) | |
| Larynx | 1 (2) | 0 | |
| Multiple myeloma | 1 (2) | 0 | |
| Hodgkin lymphoma | 1 (2) | 0 | |
| Esophagus | 0 | 1 (1) | |
| Pancreatic | 1 (2) | 0 | |
| Chemotherapyc | ns | ||
| Oxaliplatin | 29 (67) | 45 (51) | |
| Paclitaxel | 9 (21) | 15 (17) | |
| Docetaxel | 0 | 12 (14) | |
| Carboplatin | 0 | 1 (1) | |
| Cisplatin | 2 (5) | 8 (9) | |
| Vincristin | 2 (5) | 7 (8) | |
| Vinblastin | 1 (2) | 0 | |
ns Not significant
aCT−: control group of patients before the start of their treatment with chemotherapy
bCT+: patients with at least three cycles of chemotherapy
cThe CT− patients’ column represents planned chemotherapy regimens; the CT+ column represents patients that already underwent at least three cycles of chemotherapy